Forward BIOLABS and BioForward Wisconsin have partnered to launch the Innovation to Commercialization Pipeline program, a statewide initiative to help early-stage biohealth companies from discovery to market.
Companies will be provided with tools and resources to help them with commercialization barriers and capital-access gaps, reducing early risks and gaining future investment.
“In developing the program, we consistently heard from leaders how essential it is for young companies to be prepared not only to raise seed funding but also to position themselves for larger, follow-on investment,” Jessica Martin Eckerly, CEO and co-founder of Forward BIOLABS, said in a statement.
“To succeed, these emerging companies need support to hit key milestones that help them secure initial investment from Wisconsin’s early-stage investors, and continued support to bridge the gap in attracting additional capital from investors nationwide,” Martin said “The ICP program was created to help close these gaps and position Wisconsin’s biohealth companies for growth.”
The application period opens Oct. 13 and closes on Nov. 14.
